Nephrology Therapeutics
1. Afinitor patent expiration
Treatment: Treatment of solid excretory system tumors; Advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib
AFINITOR's oppositions filed in EPO
AFINITOR IPR and PTAB Proceedings
Can you believe AFINITOR received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8410131 | NOVARTIS | Cancer treatment |
Nov, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-630) | Oct 29, 2013 |
| New Chemical Entity Exclusivity(NCE) | Mar 30, 2014 |
| New Indication(I-638) | May 05, 2014 |
| New Indication(I-650) | Apr 26, 2015 |
| New Indication(I-655) | Jul 20, 2015 |
| Pediatric Exclusivity(PED) | Apr 29, 2018 |
| Orphan Drug Exclusivity(ODE) | Apr 26, 2019 |
| Orphan Drug Exclusivity(ODE-11) | May 05, 2018 |
| New Indication(I-724) | Feb 26, 2019 |
| Orphan Drug Exclusivity(ODE-24) | Apr 26, 2019 |
| Orphan Drug Exclusivity(ODE-108) | Feb 26, 2023 |
Drugs and Companies using EVEROLIMUS ingredient
NCE-1 date: 26 October, 2014
Market Authorisation Date: 09 July, 2010
Dosage: TABLET
How can I launch a generic of AFINITOR before it's drug patent expiration?
More Information on Dosage
AFINITOR family patents
2. Anjeso patent expiration
Treatment: Management of moderate-to-severe pain by intravenous injection in patients with mild renal impairment
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10881663 | BAUDAX | Method of treating pain in elderly patients with mild renal impairment |
Mar, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 20, 2023 |
Drugs and Companies using MELOXICAM ingredient
Market Authorisation Date: 20 February, 2020
Dosage: SOLUTION
More Information on Dosage
ANJESO family patents
3. Avycaz patent
expiration
Treatment: Treatment of complicated intra-abdominal infections, complicated urinary tract infections, and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in adult and pediatri...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7112592 | ABBVIE | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents |
Jan, 2026
(1 year, 1 month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-738) | Jun 22, 2019 |
| New Chemical Entity Exclusivity(NCE) | Feb 25, 2020 |
| Generating Antibiotic Incentives Now(GAIN) | Feb 25, 2025 |
| New Patient Population(NPP) | Dec 20, 2025 |
Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient
NCE-1 date: 26 February, 2024
Market Authorisation Date: 25 February, 2015
Dosage: POWDER
More Information on Dosage
AVYCAZ family patents
4. Cabometyx patent expiration
Treatment: Treatment of advanced renal cell carcinoma (rcc) in patients who have received prior anti-angiogenic therapy; Treatment of advanced renal cell carcinoma
CABOMETYX's oppositions filed in EPO
Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11141413 | EXELIXIS INC | Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate |
Apr, 2037
(12 years from now) | |
| US10039757 | EXELIXIS INC | C-Met modulator pharmaceutical compositions |
Jul, 2031
(6 years from now) | |
| US8497284 | EXELIXIS INC | C-met modulators and method of use |
Sep, 2024
(2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 29, 2017 |
| New Product(NP) | Apr 25, 2019 |
| New Indication(I-760) | Dec 19, 2020 |
| New Indication(I-792) | Jan 14, 2022 |
| New Indication(I-854) | Jan 22, 2024 |
| New Indication(I-873) | Sep 17, 2024 |
| Orphan Drug Exclusivity(ODE-227) | Jan 14, 2026 |
| Orphan Drug Exclusivity(ODE-375) | Sep 17, 2028 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
NCE-1 date: 29 November, 2016
Market Authorisation Date: 25 April, 2016
Dosage: TABLET
How can I launch a generic of CABOMETYX before it's drug patent expiration?
More Information on Dosage
CABOMETYX family patents
5. Defitelio patent expiration
Treatment: Treatment of adult and pediatric patients with hepatic veno-occlusive disease (vod), also known as sinusoidal obstruction syndrome (sos), with renal or pulmonary dysfunction following hematopoietic st...
DEFITELIO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11236328 | JAZZ PHARMS INC | Euglobulin-based method for determining the biological activity of defibrotide |
Jun, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 30, 2021 |
| Orphan Drug Exclusivity(ODE) | Mar 30, 2023 |
| Orphan Drug Exclusivity(ODE-112) | Mar 30, 2023 |
Drugs and Companies using DEFIBROTIDE SODIUM ingredient
NCE-1 date: 30 March, 2020
Market Authorisation Date: 30 March, 2016
Dosage: SOLUTION
More Information on Dosage
DEFITELIO family patents
6. Feraheme patent expiration
Treatment: Method of treating patients needing an iron supplement
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8926947 | COVIS | Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents |
Mar, 2020
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8501158 | COVIS | Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents |
Mar, 2020
(4 years ago) | |
| US8591864 | COVIS | Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents |
Mar, 2020
(4 years ago) | |
| US6599498 | COVIS | Heat stable colloidal iron oxides coated with reduced carbohydrates and carbohdrate derivatives |
Mar, 2020
(4 years ago) | |
| US7553479 | COVIS | Heat stable colloidal iron oxides coated with reduced carbohydrates and uses thereof |
Mar, 2020
(4 years ago) | |
| US7871597 | COVIS | Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents |
Mar, 2020
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 30, 2012 |
| New Indication(I-767) | Feb 02, 2021 |
Drugs and Companies using FERUMOXYTOL ingredient
Market Authorisation Date: 30 June, 2009
Dosage: SOLUTION
How can I launch a generic of FERAHEME before it's drug patent expiration?
More Information on Dosage
FERAHEME family patents
7. Fosrenol patent expiration
Treatment: Reduction of serum phosphate in patients with end stage renal disease
FOSRENOL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7381428 | TAKEDA PHARMS USA | Stabilized lanthanum carbonate compositions |
Aug, 2024
(3 months ago) | |
Drugs and Companies using LANTHANUM CARBONATE ingredient
Market Authorisation Date: 23 November, 2005
Dosage: TABLET, CHEWABLE
How can I launch a generic of FOSRENOL before it's drug patent expiration?
More Information on Dosage
FOSRENOL family patents
8. Fotivda patent expiration
Treatment: Treatment of adults with moderate hepatic impairment and relapsed or refractory advanced renal cell carcinoma following two or more prior systemic anti-cancer therapies with 1mg tivozanib hcl orally f...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6821987 | AVEO PHARMS | Quinoline derivatives and quinazoline derivatives having azolyl group |
Apr, 2025
(4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11504365 | AVEO PHARMS | Use of tivozanib to treat subjects with refractory cancer |
Nov, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 10, 2026 |
Drugs and Companies using TIVOZANIB HYDROCHLORIDE ingredient
NCE-1 date: 10 March, 2025
Market Authorisation Date: 10 March, 2021
Dosage: CAPSULE
More Information on Dosage
FOTIVDA family patents
9. Gelnique patent expiration
Treatment: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence with a single unit dose of 10% oxybutynin chloride gel
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10449173 | ABBVIE | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Nov, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jan 27, 2012 |
Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient
Market Authorisation Date: 27 January, 2009
Dosage: GEL
How can I launch a generic of GELNIQUE before it's drug patent expiration?
More Information on Dosage
GELNIQUE family patents
10. Gemtesa patent expiration
Treatment: Treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8247415 | UROVANT | Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists |
Dec, 2030
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12102638 | UROVANT | Use of vibegron to treat overactive bladder |
Mar, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2025 |
Drugs and Companies using VIBEGRON ingredient
NCE-1 date: 23 December, 2024
Market Authorisation Date: 23 December, 2020
Dosage: TABLET
More Information on Dosage
GEMTESA family patents
11. Glyxambi patent expiration
Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of tr...
GLYXAMBI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11833166 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jan 30, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient
NCE-1 date: 01 August, 2018
Market Authorisation Date: 30 January, 2015
Dosage: TABLET
How can I launch a generic of GLYXAMBI before it's drug patent expiration?
More Information on Dosage
GLYXAMBI family patents
12. Goprelto patent expiration
Treatment: Method of administering a local anesthetic prior to performing a diagnostic or surgical procedure on a subject with hepatic or renal impairment; Method of administering a local anesthetic to the mucou...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10016407 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10973811 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2022 |
Drugs and Companies using COCAINE HYDROCHLORIDE ingredient
NCE-1 date: 14 December, 2021
Market Authorisation Date: 14 December, 2017
Dosage: SOLUTION
More Information on Dosage
GOPRELTO family patents
13. Injectafer patent expiration
Treatment: Method to treat iron deficiency anemia in adults with non-dialysis dependent chronic kidney disease & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least 0...
INJECTAFER's oppositions filed in EPO
INJECTAFER IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11590097 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(1 year, 1 month ago) | |
| US11291645 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(1 year, 1 month ago) | |
| US11123321 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(1 year, 1 month ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11478502 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(2 years from now) | |
| US7754702 | AM REGENT | Methods and compositions for administration of iron |
Feb, 2028
(3 years from now) | |
| US8895612 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 25, 2016 |
| New Strength(NS) | Apr 28, 2024 |
| New Patient Population(NPP) | Nov 19, 2024 |
| New Indication(I-915) | May 31, 2026 |
Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient
Market Authorisation Date: 28 April, 2021
Dosage: SOLUTION
How can I launch a generic of INJECTAFER before it's drug patent expiration?
More Information on Dosage
INJECTAFER family patents
14. Inlyta patent expiration
Treatment: Treatment of renal cell carcinoma; Axitinib in combination with avelumab for the first-line treatment of patients with advanced renal cell carcinoma; In combination with pembrolizumab for the first-li...
INLYTA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7141581 | PF PRISM CV | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
Jun, 2020
(4 years ago) | |
| US10869924 | PF PRISM CV | PD-L1 antagonist combination treatments |
Jan, 2037
(12 years from now) | |
| US10570202 | PF PRISM CV | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
Feb, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 27, 2017 |
Drugs and Companies using AXITINIB ingredient
NCE-1 date: 28 January, 2016
Market Authorisation Date: 27 January, 2012
Dosage: TABLET
How can I launch a generic of INLYTA before it's drug patent expiration?
More Information on Dosage
INLYTA family patents
15. Inpefa patent expiration
Treatment: Reduction of risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardi...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8476413 | LEXICON PHARMS INC | Sulfanyl-tetrahydropyran-based compounds and methods of their use |
May, 2028
(3 years from now) | |
| US7781577 | LEXICON PHARMS INC | Inhibitors of sodium glucose co-transporter 2 and methods of their use |
May, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 26, 2028 |
Drugs and Companies using SOTAGLIFLOZIN ingredient
NCE-1 date: 27 May, 2027
Market Authorisation Date: 26 May, 2023
Dosage: TABLET
More Information on Dosage
INPEFA family patents
16. Invokamet patent expiration
Treatment: Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients
INVOKAMET's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(2 years from now) | |
| US7943582 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Feb, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Aug 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-735) | May 20, 2019 |
| M(M-197) | Feb 01, 2020 |
| New Indication(I-788) | Oct 29, 2021 |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 29 March, 2017
Market Authorisation Date: 08 August, 2014
Dosage: TABLET
How can I launch a generic of INVOKAMET before it's drug patent expiration?
More Information on Dosage
INVOKAMET family patents
17. Invokamet Xr patent expiration
Treatment: Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients
INVOKAMET XR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7943582 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Feb, 2029
(4 years from now) | |
| US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Aug 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-735) | May 20, 2019 |
| New Indication(I-788) | Oct 29, 2021 |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 29 March, 2017
Market Authorisation Date: 20 September, 2016
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of INVOKAMET XR before it's drug patent expiration?
More Information on Dosage
INVOKAMET XR family patents
18. Invokana patent expiration
Treatment: Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients; Reductio...
INVOKANA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(4 months from now) | |
| US10617668 | JANSSEN PHARMS | Pharmaceutical formulations |
May, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-733) | May 20, 2019 |
| M(M-197) | Feb 01, 2020 |
| New Indication(I-788) | Oct 29, 2021 |
| New Indication(I-809) | Sep 27, 2022 |
Drugs and Companies using CANAGLIFLOZIN ingredient
NCE-1 date: 29 March, 2017
Market Authorisation Date: 29 March, 2013
Dosage: TABLET
How can I launch a generic of INVOKANA before it's drug patent expiration?
More Information on Dosage
INVOKANA family patents
19. Jardiance patent expiration
Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of tr...
JARDIANCE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(9 years from now) | |
| US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11833166 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11666590 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-159) | Jun 26, 2018 |
| M(M-160) | Jun 26, 2018 |
| M(M-161) | Jun 26, 2018 |
| M(M-174) | Mar 18, 2019 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| New Indication(I-869) | Aug 18, 2024 |
| M(M-82) | Feb 24, 2025 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| New Patient Population(NPP) | Jun 20, 2026 |
| New Indication(I-922) | Sep 21, 2026 |
Drugs and Companies using EMPAGLIFLOZIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 01 August, 2014
Dosage: TABLET
How can I launch a generic of JARDIANCE before it's drug patent expiration?
More Information on Dosage
JARDIANCE family patents
20. Jesduvroq patent expiration
Treatment: Treatment of anemia due to chronic kidney disease
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8815884 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Jun, 2027
(2 years from now) | |
| US8557834 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Jun, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 01, 2028 |
Drugs and Companies using DAPRODUSTAT ingredient
NCE-1 date: 01 February, 2027
Market Authorisation Date: 01 February, 2023
Dosage: TABLET
More Information on Dosage
JESDUVROQ family patents
21. Korsuva patent expiration
Treatment: Treatment of moderate-to-severe pruritus associated with chronic kidney disease (ckd-ap) in adults undergoing hemodialysis (hd)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10793596 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(2 years from now) | |
| US10017536 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(2 years from now) | |
| US8536131 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(2 years from now) | |
| US7727963 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(2 years from now) | |
| US7713937 | CARA THERAP | Synthetic peptide amides and dimeric forms thereof |
Nov, 2027
(2 years from now) | |
| US7402564 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10138270 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(2 years from now) | |
| US9334305 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(2 years from now) | |
| US8486894 | CARA THERAP | Synthetic peptide amides and dimeric forms thereof |
Nov, 2027
(2 years from now) | |
| US8217007 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(2 years from now) | |
| US9359399 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(2 years from now) | |
| US8236766 | CARA THERAP | Uses of synthetic peptide amides |
Nov, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 23, 2026 |
Drugs and Companies using DIFELIKEFALIN ACETATE ingredient
NCE-1 date: 23 August, 2025
Market Authorisation Date: 23 August, 2021
Dosage: SOLUTION
More Information on Dosage
KORSUVA family patents
22. Livtencity patent expiration
Treatment: Treatment of patients with post-transplant cytomegalovirus (cmv) infection/disease refractory to treatment with ganciclovir, valganciclovir, cidofovir, or foscarnet, where the patient is a stem cell, ...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11684632 | TAKEDA PHARMS USA | Maribavir isomers, compositions, methods of making and methods of using |
Jan, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 23, 2026 |
| Orphan Drug Exclusivity(ODE-388) | Nov 23, 2028 |
Drugs and Companies using MARIBAVIR ingredient
NCE-1 date: 23 November, 2025
Market Authorisation Date: 23 November, 2021
Dosage: TABLET
More Information on Dosage
LIVTENCITY family patents
23. Lonsurf patent expiration
Treatment: Treatment of metastatic colorectal cancer alone or with bevacizumab in severely renally impaired patients previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan therapy, an anti-vegf b...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10456399 | TAIHO ONCOLOGY | Method for treating cancer patients with severe renal impairment |
Feb, 2037
(12 years from now) | |
| US10960004 | TAIHO ONCOLOGY | Method for treating cancer patients with severe renal impairment |
Feb, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 22, 2020 |
| New Indication(I-794) | Feb 22, 2022 |
| Orphan Drug Exclusivity(ODE-229) | Feb 22, 2026 |
Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient
NCE-1 date: 23 September, 2019
Market Authorisation Date: 22 September, 2015
Dosage: TABLET
How can I launch a generic of LONSURF before it's drug patent expiration?
More Information on Dosage
LONSURF family patents
24. Monoferric patent expiration
Treatment: Treatment of iron deficiency anemia (dia) in adults patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, who have non-hemodialysis dependent chronic kidney dise...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8815301 | PHARMACOSMOS | Stable iron oligosaccharide compound |
Aug, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11633489 | PHARMACOSMOS | Iron carbohydrate complex for treatment of iron deficiency of a fetus or an infant |
Jun, 2036
(11 years from now) | |
Drugs and Companies using FERRIC DERISOMALTOSE ingredient
Market Authorisation Date: 16 January, 2020
Dosage: SOLUTION
More Information on Dosage
MONOFERRIC family patents
25. Myrbetriq patent expiration
Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency; For the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, a...
MYRBETRIQ's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7750029 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Dec, 2023
(11 months ago) | |
| US8835474 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Nov, 2023
(1 year, 30 days ago) | |
| USRE44872 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Nov, 2023
(1 year, 30 days ago) | |
| US8772315 | APGDI | Pharmaceutical composition for treating overactive bladder |
Oct, 2028
(3 years from now) | |
| US10842780 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 28, 2017 |
| New Indication(I-777) | Apr 27, 2021 |
| New Indication(I-855) | Mar 25, 2024 |
| Pediatric Exclusivity(PED) | Sep 25, 2024 |
Drugs and Companies using MIRABEGRON ingredient
NCE-1 date: 26 September, 2023
Market Authorisation Date: 28 June, 2012
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of MYRBETRIQ before it's drug patent expiration?
More Information on Dosage
MYRBETRIQ family patents
26. Nexavar patent expiration
Treatment: Treatment of advanced renal cell carcinoma; Treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, or differentiated thyroid carcinoma.
NEXAVAR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8877933 | BAYER HLTHCARE | Thermodynamically stable form of a tosylate salt |
Dec, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8618141 | BAYER HLTHCARE | Aryl ureas with angiogenesis inhibiting activity |
Feb, 2023
(1 year, 9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Dec 20, 2012 |
| New Indication(I-677) | Nov 22, 2016 |
| Orphan Drug Exclusivity(ODE-56) | Nov 22, 2020 |
Drugs and Companies using SORAFENIB TOSYLATE ingredient
Market Authorisation Date: 20 December, 2005
Dosage: TABLET
How can I launch a generic of NEXAVAR before it's drug patent expiration?
More Information on Dosage
NEXAVAR family patents
27. Normocarb Hf 25 patent expiration
Treatment: Use as replacement solution, hemofiltration solution or hemodiafiltration solution in continuous renal replacement therapy
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5945449 | DIALYSIS SUPS | Sterile bicarbonate concentrate |
Oct, 2017
(7 years ago) | |
| US7300674 | DIALYSIS SUPS | Sterile low bicarbonate dialysis concentrate solutions |
Mar, 2023
(1 year, 9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jul 26, 2013 |
Drugs and Companies using MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE ingredient
Market Authorisation Date: 26 July, 2006
Dosage: SOLUTION
More Information on Dosage
NORMOCARB HF 25 family patents
28. Normocarb Hf 35 patent expiration
Treatment: Use as replacement solution, hemofiltration solution or hemodiafiltration solution in continuous renal replacement therapy
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5945449 | DIALYSIS SUPS | Sterile bicarbonate concentrate |
Oct, 2017
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jul 26, 2013 |
Drugs and Companies using MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE ingredient
Market Authorisation Date: 26 July, 2006
Dosage: SOLUTION
More Information on Dosage
NORMOCARB HF 35 family patents
29. Numbrino patent expiration
Treatment: Method of administering a local anesthetic to the mucous membranes in patients with renal impairment; Method of administering a local anesthetic prior to performing a diagnostic or surgical procedure ...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9867815 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10016407 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2022 |
| New Product(NP) | Jan 10, 2023 |
Drugs and Companies using COCAINE HYDROCHLORIDE ingredient
NCE-1 date: 14 December, 2021
Market Authorisation Date: 10 January, 2020
Dosage: SOLUTION
More Information on Dosage
NUMBRINO family patents
30. Omontys patent expiration
Treatment: Treatment of anemia due to chronic kidney disease
Can you believe OMONTYS received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7084245 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(6 months ago) | |
| US7414105 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(6 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7550433 | TAKEDA PHARMS USA | Erythropoietin receptor peptide formulations and uses |
Jun, 2026
(1 year, 5 months from now) | |
| US7919461 | TAKEDA PHARMS USA | Erythropoietin receptor peptide formulations and uses |
Jun, 2026
(1 year, 5 months from now) | |
Drugs and Companies using PEGINESATIDE ACETATE ingredient
NCE-1 date: 27 March, 2016
Market Authorisation Date: 27 March, 2012
Dosage: SOLUTION
More Information on Dosage
OMONTYS family patents
31. Omontys Preservative Free patent expiration
Treatment: Treatment of anemia due to chronic kidney disease
Can you believe OMONTYS PRESERVATIVE FREE received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7084245 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(6 months ago) | |
| US7414105 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(6 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7550433 | TAKEDA PHARMS USA | Erythropoietin receptor peptide formulations and uses |
Jun, 2026
(1 year, 5 months from now) | |
| US7919461 | TAKEDA PHARMS USA | Erythropoietin receptor peptide formulations and uses |
Jun, 2026
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 27, 2017 |
Drugs and Companies using PEGINESATIDE ACETATE ingredient
NCE-1 date: 27 March, 2016
Market Authorisation Date: 27 March, 2012
Dosage: SOLUTION
More Information on Dosage
OMONTYS PRESERVATIVE FREE family patents
32. Opana Er patent expiration
Treatment: Dose modification for renal impairment
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8808737 | ENDO OPERATIONS | Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment |
Jun, 2027
(2 years from now) | |
Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 22 June, 2006
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
OPANA ER family patents
33. Rayaldee patent expiration
Treatment: Use of controlled release 25-hydroxyvitamin d in treating secondary hyperparathyroidism in patients having chronic kidney disease; Treatment of secondary hyperparathyroidism in patients with stage 3 o...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9408858 | EIRGEN | Method for treating secondary hyperparathyroidism in CKD |
Apr, 2028
(3 years from now) | |
| US8207149 | EIRGEN | Method for treating secondary hyperparathyroidism in CKD |
Apr, 2028
(3 years from now) | |
| US11801253 | EIRGEN | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
Sep, 2030
(5 years from now) | |
| US9498486 | EIRGEN | Method for controlled release oral dosage of a vitamin D compound |
Apr, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 17, 2019 |
Drugs and Companies using CALCIFEDIOL ingredient
Market Authorisation Date: 17 June, 2016
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
RAYALDEE family patents
34. Recarbrio patent expiration
Treatment: Treatment of complicated urinary tract infections, including pyelonephritis (cuti)
Can you believe RECARBRIO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8487093 | MSD MERCK CO | β-lactamase inhibitors |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 16, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Jul 16, 2029 |
Drugs and Companies using CILASTATIN SODIUM; IMIPENEM; RELEBACTAM ingredient
NCE-1 date: 16 July, 2028
Market Authorisation Date: 16 July, 2019
Dosage: POWDER
More Information on Dosage
RECARBRIO family patents
35. Recorlev patent expiration
Treatment: During levoketoconazole dosage titration for the treatment of cushing's syndrome in patients who concomitantly use metformin, monitoring glycemia, kidney function and vitamin b-12 and adjusting dosage...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11278547 | STRONGBRIDGE | Methods of treating disease with levoketoconazole |
Mar, 2040
(15 years from now) | |
| US11020393 | STRONGBRIDGE | Methods of treating disease with levoketoconazole |
Mar, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-385) | Dec 30, 2028 |
Drugs and Companies using LEVOKETOCONAZOLE ingredient
Market Authorisation Date: 30 December, 2021
Dosage: TABLET
More Information on Dosage
RECORLEV family patents
36. Sunosi patent expiration
Treatment: Treatment of excessive daytime sleepiness by administering solriamfetol to a subject having mild, moderate, or severe renal impairment; Treatment of excessive daytime sleepiness associated with obstru...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11160779 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
| US10940133 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
| US11839599 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
| US11839598 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
| US11850226 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
| US11850227 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
| US11850228 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
| US11857528 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
| US11986455 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
| US11986454 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-254) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: 18 June, 2023
Market Authorisation Date: 17 June, 2019
Dosage: TABLET
How can I launch a generic of SUNOSI before it's drug patent expiration?
More Information on Dosage
SUNOSI family patents
37. Synjardy patent expiration
Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Treating typ...
SYNJARDY's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11833166 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 26, 2018 |
| M(M-174) | Mar 18, 2019 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| New Patient Population(NPP) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 26 August, 2015
Dosage: TABLET
How can I launch a generic of SYNJARDY before it's drug patent expiration?
More Information on Dosage
SYNJARDY family patents
38. Synjardy Xr patent expiration
Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Treating typ...
SYNJARDY XR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(9 years from now) | |
| US11833166 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| M(M-296) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 09 December, 2016
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of SYNJARDY XR before it's drug patent expiration?
More Information on Dosage
SYNJARDY XR family patents
39. Tarpeyo patent expiration
Treatment: Reduction in loss of kidney function and reduction of proteinuria in adults with primary immunoglobulin a nephropathy (igan) who are at risk of disease progression, by release of budesonide from the f...
TARPEYO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11896719 | CALLIDITAS | Pharmaceutical compositions |
Jan, 2043
(18 years from now) | |
| US8491932 | CALLIDITAS | Compositions for the oral delivery of corticosteroids |
May, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 15, 2024 |
| Orphan Drug Exclusivity(ODE-389) | Dec 15, 2028 |
| Orphan Drug Exclusivity(ODE-464) | Dec 20, 2030 |
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 15 December, 2021
Dosage: CAPSULE, DELAYED RELEASE
More Information on Dosage
TARPEYO family patents
40. Terlivaz patent expiration
Treatment: A method to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10335452 | MALLINCKRODT IRELAND | Method of treating patients with hepatorenal syndrome type 1 |
Apr, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 14, 2027 |
| Orphan Drug Exclusivity(ODE-406) | Sep 14, 2029 |
Drugs and Companies using TERLIPRESSIN ACETATE ingredient
NCE-1 date: 14 September, 2026
Market Authorisation Date: 14 September, 2022
Dosage: POWDER
More Information on Dosage
TERLIVAZ family patents
41. Torisel patent expiration
Treatment: Method of treating metastatic papillary renal cell carcinoma with temsirolimus.
TORISEL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8791097 | PF PRISM CV | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
May, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-91) | Apr 26, 2013 |
| M(M-92) | Jul 09, 2013 |
| Pediatric Exclusivity(PED) | Jan 09, 2014 |
| Orphan Drug Exclusivity(ODE) | May 30, 2014 |
| M(M-61) | May 30, 2015 |
Drugs and Companies using TEMSIROLIMUS ingredient
Market Authorisation Date: 30 May, 2007
Dosage: SOLUTION
How can I launch a generic of TORISEL before it's drug patent expiration?
More Information on Dosage
TORISEL family patents
42. Toviaz patent expiration
Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency
TOVIAZ IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6858650 | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jul, 2022
(2 years ago) | |
| US7384980 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(5 years ago) | |
| US7985772 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(5 years ago) | |
| US7855230 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(5 years ago) | |
| US8338478 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(5 years ago) | |
| US7807715 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(2 years from now) | |
| US8088398 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2013 |
| New Indication(I-861) | Jun 17, 2024 |
| Pediatric Exclusivity(PED) | Dec 17, 2024 |
Drugs and Companies using FESOTERODINE FUMARATE ingredient
NCE-1 date: 18 December, 2023
Market Authorisation Date: 31 October, 2008
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of TOVIAZ before it's drug patent expiration?
More Information on Dosage
TOVIAZ family patents
43. Tradjenta patent expiration
Treatment: Method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and for whom metformin therapy is inappropriate by administering linagliptin; Method of treating type 2 dia...
TRADJENTA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8853156 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Mar, 2031
(6 years from now) | |
| US9486526 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Aug, 2029
(4 years from now) | |
| US10034877 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Aug, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-118) | Aug 13, 2015 |
| M(M-121) | Aug 13, 2015 |
| New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 02 May, 2011
Dosage: TABLET
How can I launch a generic of TRADJENTA before it's drug patent expiration?
More Information on Dosage
TRADJENTA family patents
44. Trijardy Xr patent expiration
Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin in combinatio...
TRIJARDY XR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(9 years from now) | |
| US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11833166 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 January, 2020
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of TRIJARDY XR before it's drug patent expiration?
More Information on Dosage
TRIJARDY XR family patents
45. Ubrelvy patent expiration
Treatment: Acute treatment of migraine with or without aura in a patient with severe renal impairment
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11857542 | ABBVIE | Treatment of migraine |
Dec, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2024 |
Drugs and Companies using UBROGEPANT ingredient
NCE-1 date: 24 December, 2023
Market Authorisation Date: 23 December, 2019
Dosage: TABLET
More Information on Dosage
UBRELVY family patents
46. Vabomere patent expiration
Treatment: Treatment of complicated urinary tract infections (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli,klebsiella pneumonia,enterobacter cloacae species...
VABOMERE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11376237 | REMPEX | Methods of treating bacterial infections |
Apr, 2039
(14 years from now) | |
| US10183034 | REMPEX | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives |
Aug, 2031
(6 years from now) | |
| US11007206 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(6 years from now) | |
| US9694025 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(6 years from now) | |
| US10561675 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 29, 2022 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 29, 2027 |
Drugs and Companies using MEROPENEM; VABORBACTAM ingredient
NCE-1 date: 29 August, 2026
Market Authorisation Date: 29 August, 2017
Dosage: POWDER
More Information on Dosage
VABOMERE family patents
47. Welireg patent expiration
Treatment: Treatment of adult patients with advanced renal cell carcinoma following a programmed death receptor-1 or programmed death-ligand inhibitor and a vascular endothelial growth factor tyrosine kinase inh...
Can you believe WELIREG received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE49948 | MERCK SHARP DOHME | Aryl ethers and uses thereof |
Sep, 2034
(9 years from now) | |
| US9969689 | MERCK SHARP DOHME | Aryl ethers and uses thereof |
Sep, 2034
(9 years from now) | |
| US9908845 | MERCK SHARP DOHME | Aryl ethers and uses thereof |
Sep, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2026 |
| New Indication(I-931) | Dec 14, 2026 |
| Orphan Drug Exclusivity(ODE-364) | Aug 13, 2028 |
Drugs and Companies using BELZUTIFAN ingredient
NCE-1 date: 13 August, 2025
Market Authorisation Date: 13 August, 2021
Dosage: TABLET
More Information on Dosage
WELIREG family patents
48. Zerbaxa patent expiration
Treatment: Treatment of complicated intra-abdominal infection in patients with end-stage renal disease on hemodialysis; Treatment of hospital-acquired bacterial pneumonia in patients with end-stage renal disease...
ZERBAXA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10376496 | CUBIST PHARMS LLC | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
Sep, 2034
(9 years from now) | |
| US10933053 | CUBIST PHARMS LLC | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
Sep, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
| Generating Antibiotic Incentives Now(GAIN) | Dec 19, 2024 |
| New Patient Population(NPP) | Apr 21, 2025 |
Drugs and Companies using CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM ingredient
NCE-1 date: 20 December, 2023
Market Authorisation Date: 19 December, 2014
Dosage: POWDER
More Information on Dosage
ZERBAXA family patents